1 The effect of neoadjuvant therapy on PD-L1 expression and

2 CD8 lymphocyte density in non-small cell lung cancer

- 3 Philipp Zens^{a, b}, Corina Bello^{a, 1}, Amina Scherz^c, Michael von Gunten^d, Adrian
- 4 Ochsenbein^c, Ralph A Schmid^e, Sabina Berezowska^{a, f}
- 5 ^a Institute of Pathology, University of Bern, Bern, Switzerland
- 6 ^b Graduate School for Health Science, University of Bern, Bern, Switzerland
- 7 ^c Department of Medical Oncology, Inselspital, Bern University Hospital, Bern,
- 8 Switzerland
- 9 ^d Pathology Länggasse, Bern, Switzerland
- 10 ^e Department of General Thoracic Surgery, Inselspital, Bern University Hospital,
- 11 Bern, Switzerland
- 12 ^f Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne
- 13 University Hospital and Lausanne University, Lausanne, Switzerland
- 14 ¹ Present address: Department for anesthesiology, Hospital Grabs, Spitalstrasse 44,
- 15 CH-9472 Grabs, Switzerland
- 16 Running title: PD-L1 and TILs in NSCLC after neoadjuvant therapy

17 Corresponding Author

- 18 Prof. Dr. Sabina Berezowska
- 19 Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne
- 20 University Hospital and Lausanne University
- 21 Rue du Bugnon 25, 1011 Lausanne, Switzerland
- 22 Email: sabina.berezowska@chuv.ch
- 23 Phone: +41 (0)21 314 72 11
- 24 ORCID ID: 0000-0001-5442-9791
- 25
- 26 Preliminary results have been presented at the World Conference on Lung Cancer,
- 27 September 7th 10th 2019 in Barcelona, Spain.
- 28

29 Competing Interests

- 30 SB has served as compensated consultant for Basilea, Eli Lilly, MSD and Roche
- 31 (payment to institution) and has received research funding from Roche outside of the
- 32 current project. The other authors declare no conflict of interest.

33 Abstract

34 PD-L1 expression is the routine clinical biomarker for the selection of patients to 35 receive immunotherapy in non-small cell lung cancer (NSCLC). However, the 36 application and best timing of immunotherapy in the resectable setting is still under 37 investigation. We aimed to study the effect of chemotherapy on PD-L1 expression 38 and tumor infiltrating lymphocytes (TIL), which is to date still poorly understood. 39 This retrospective, single-centre study cohort comprised 96 consecutive patients with 40 NSCLC resected in 2000-2016 after neoadjuvant therapy, including paired chemo-41 naïve specimens in 57 cases. A biologically matched control cohort of 114 primary 42 resected cases was included. PD-L1 expression, CD8+ TIL density and tertiary 43 lymphoid structures were assessed on whole slides and correlated with clinico-44 pathological characteristics and survival. 45 Seven/57 and 12/57 cases had lower respectively higher PD-L1 expressions after 46 neoadjuvant therapy. Most cases (n = 38) had no changes in PD-L1 expression and 47 the majority of these showed PD-L1 < 1% in both samples (23/38 [60.5%]). CD8+ 48 TILs density was significantly higher after chemotherapy (p = 0.031) in paired 49 resections. Neoadjuvant cases showed no difference in PD-L1 expression or CD8+ 50 TILs density compared to the chemotherapy naïve control cohort. In univariable 51 analyses, higher CD8+ TILs density, higher numbers of tertiary lymphoid structures 52 but not PD-L1 expression were significantly associated with better survival. Increased 53 PD-L1 expression after neoadjuvant chemotherapy was visually associated with 54 worse 5-year survival, lacking statistical significance probably due to the low number 55 of cases.

- 56 PD-L1 expression is mostly unchanged after neoadjuvant chemotherapy. However,
- 57 an increase of PD-L1 expression after neoadjuvant therapy could be associated with
- 58 worse survival.

59 Introduction

60 Lung cancer is the deadliest cancer worldwide, mainly explainable by the late 61 diagnosis due to presentation in advanced stages (UICC/AJCC TNM stage III/IV) (1). 62 For early-stage non-small cell lung cancer (NSCLC), surgery still offers the best 63 chance of cure (2). However, especially in nodal-positive patients, there is a high risk 64 of recurrence and death. Since randomized trials have shown that additional 65 neoadjuvant or adjuvant chemotherapy leads to better outcomes compared to 66 resection only, it is generally accepted that patients with lymph node metastatic 67 NSCLC should not receive surgery as a stand-alone treatment (3, 4). Adjuvant 68 platinum-based chemotherapy offers a modest 5-year survival benefit of about 5% 69 and is recommended for patients with completely resected early-stage, high-risk 70 NSCLC – weighing the benefits and risks (5). Perioperative therapeutic approaches 71 are a hotly debated topic, with immunotherapy-based combinations and targeted 72 treatments – in EGFR mutated NSCLC – dominating the current trial landscape. 73 According to surgical outcomes from the phase III CheckMate 816 trial, the 74 neoadjuvant combination of nivolumab and chemotherapy showed considerably 75 lower rates of residual tumor compared with chemotherapy alone (6). Primary results 76 of the phase III global IMpower010 trial demonstrated a significant improvement in 77 disease-free survival (DFS) comparing atezolizumab with best supportive care after 78 adjuvant chemotherapy for resected stage IB – IIIA NSCLC. The greatest benefit was 79 observed in patients with a tumoral programmed cell death 1 ligand 1 (PD-L1) 80 expression (TPS) $\geq 1\%$ (7). 81 Programmed cell death protein 1 (PD1) and its ligand PD-L1 belong to the 82 costimulatory pathway of the adapted immune system (8). Extensive studies have 83 explained the hijacking of this regulatory pathway by different tumor entities including

84 lung cancer (8). PD1 is expressed on the surface of T cells, mediating inhibitory and 85 stimulatory signals (8). The overexpression of PD-L1 on the surface of tumor cells 86 leads to evasion of an appropriate tumor-induced response of the immune system by 87 T cell apoptosis and exhaustion (8). The combination of immune checkpoint blockade 88 and chemotherapy seems to be beneficial especially in patients with low levels of 89 PD-L1 expressing tumor cells and ongoing trials are reporting positive results of this 90 regimen in patients with resectable lung cancer (6, 9). However, the selection of 91 appropriate patients is currently based only on PD-L1 expression in tumor tissue prior 92 to medication, which is a suboptimal biomarker. More selective tools or, conceivably, 93 a combination of multiple tumor immunity markers such as tumor mutational burden 94 or CD8+ tumor infiltrating lymphocytes (TILs) are needed to predict response to 95 treatment. This is highlighted by recent examples of immune checkpoint blockade 96 (ICB) benefit irrespective of tumoral PD-L1 expression (10). Furthermore, it is still 97 unclear how classic neoadjuvant chemotherapy influences the tumor 98 microenvironment and if it could promote therapeutic ICB. Regarding the 99 neoadjuvant setting, several studies have reported dynamic changes, though without 100 a clear trend of altered PD-L1 expression after chemotherapy (Table 1) (11-22). 101 These results contrast preclinical data substantiating an immunogenic effect to some 102 chemotherapeutic agents and functional studies reporting the mechanisms involved 103 in chemotherapy resistance and PD-L1 upregulation (14, 19, 23). 104 Here, we aimed to assess PD-L1 expression and CD8+ TILs density and their 105 prognostic importance in a real-life cohort of patients with NSCLC resected after 106 neoadjuvant chemo(radio)therapy compared to paired diagnostic samples and a 107 biologically matched control cohort with primary resected advanced NSCLC.

108 Material and Methods

109 Study population

110 This retrospective single center study was conducted on consecutive patients with 111 NSCLCs, resected between January 2000 and December 2016 in the Department of 112 thoracic surgery of the Inselspital and diagnosed at the Institute of Pathology, 113 University of Bern as previously described (24). It includes a study cohort of cases 114 resected after neoadjuvant therapy and a biologically matched control cohort of 115 primary resected cases of lung squamous cell carcinoma (LUSC) and lung 116 adenocarcinoma (LUAD) at a locally advanced stage, defined by the presence of 117 mediastinal lymph-node metastases (pN2) (25). The cases were included according 118 to pathology reports, validated and expanded by considering the clinical files of the 119 Inselspital Bern (clinical data), cantonal cancer registry of Bern (survival data) and by 120 contacting the general practitioners (clinical and survival data). 121 The initial study cohort consisted of 131 cases and was reduced to 119 cases 122 corresponding to 118 patients after excluding tumors with neuroendocrine histology 123 and patients not treated with neoadjuvant intention. Finally, 22/118 patients were 124 excluded due to insufficient residual tumor in any of the diagnostic blocks resulting in 125 96 patients included for evaluation of tumoral PD-L1 expression and CD8+ TILs and 126 95 patients for evaluation of tertiary lymphoid structures (TLS). Regarding pre-127 neoadjuvant therapy specimens, 86/118 patients had available diagnostic biopsies or 128 cytology specimens, in 57 cases with sufficient tumor content for PD-L1 assessment 129 and in 36 cases with adequate material for CD8+ TILs evaluation, excluding 130 cytologies and lymph node biopsies without desmoplastic reaction. TLS were not 131 evaluated in the pretherapeutic specimens.

- 132 The initial control cohort consisted of 115 cases including 60 patients with LUAD and
- 133 55 patients with LUSC. One case was excluded from further evaluation because of

134 insufficient tumor present in the diagnostic blocks. Finally, 114 patients were included

- 135 for PD-L1 evaluation and 111 patients for CD8 and TLS evaluation (3 patients
- 136 missing due to repeatedly insufficient scanning quality).
- 137 For harmonization, all cases were pathologically re-evaluated by SB and PZ and re-
- 138 staged according to the current 8th edition of the UICC TNM classification (25).
- Additionally, the predominant growth pattern was assessed for primary resected
- 140 LUAD cases according to the current 2021 World Health Organization criteria (26).
- 141 Table 2 summarizes the baseline characteristics of the cohorts.
- 142 This study was carried out according to the REMARK criteria and approved by the
- 143 Cantonal Ethics Commission of the Canton of Bern (KEK 2017-00830), which waived
- 144 the requirement for written informed consent (27).

145 Survival Analyses

146 We restricted the survival analyses to five years after initial diagnosis to account for 147 the multimorbidity of older patients. Overall survival (OS) was defined as the period 148 from the beginning of treatment to death of any cause. DFS was defined as the 149 period from the beginning of treatment to clinically reported relapse or death of any 150 cause. The beginning of treatment was defined by the start of neoadjuvant therapy in 151 the study cohort or the date of resection in the control cohort and in 2 cases with missing information about the starting date of neoadjuvant therapy. Patients with 152 153 stage IV disease (n = 14), missing survival information (n = 7), non-curative resection 154 (n = 2) or last follow-up information within 30 days after surgery (n = 12) were 155 excluded from survival analyses resulting in 175 patients included (study cohort n = 156 83, control cohort n = 92). Median OS was 35 (95% CI 29 – NA) months and 87

events were observed (Supplementary figure 1A). Median DFS was 18 (95% CI 15 –
25) months and 118 events were observed (Supplementary figure 1B). There was no
significant difference of survival between the study cohort and the control cohort
(Supplementary figure 1C/1D).

161 *Immunohistochemical staining and scanning*

162 For immunohistochemical staining appropriate tissue blocks were selected after 163 screening all available H&E slides. PD-L1 staining was effectuated in a closed 164 system using the Ventana SP263 assay (Roche Diagnostics International AG, 165 Rotkreuz, Switzerland) on the fully automated immunostainer BenchMark ULTRA 166 (Roche Diagnostics International AG) following the manufacturer's instructions. The 167 sections were pre-processed using CC1 buffer at 100°C for 64 minutes, followed by 168 antibody incubation at 37°C for 16 minutes and visualization with DAB. CD8 staining 169 was effectuated on a fully automated immunostainer BOND III (Leica Biosystems, 170 Muttenz, Switzerland) using C8/144B (Agilent, Santa Clara, CA, United States). The 171 sections were pre-processed with ER2 buffer at 100°C for 20 minutes, followed by 172 incubation of the diluted antibody (1:200) for 15 minutes and visualization with DAB. 173 Selected slides were digitized using the Pannoramic P250 Flash III (3DHistech, 174 Budapest, Hungary) in multiple runs at a resolution of 0.2431 µm/pixel. 175 The tissue had been obtained during the routine diagnostic workflow and the 176 formalin-fixed paraffin-embedded tissue had been stored at the Institute of Pathology 177 Bern according to the recommendation of the Swiss Society of Pathology (28). There 178 was no evidence of time-dependent staining bias with similar distributions of PD-L1 179 or CD8 expression along the period of observation (Supplementary figure 2A/2B).

180 PD-L1 assessment

181 Specimens with at least 100 tumor cells were eligible. PD-L1 expression was 182 assessed by PZ and reviewed on a double-headed microscope together with SB. In 183 cases of discordant assessment consensus was achieved. PD-L1 expression was 184 assessed as the tumor proportional score (TPS), defined by the proportion of PD-L1 185 positive tumor cells of all tumor cells. PD-L1 positive tumor cells were defined as 186 showing membranous staining of any intensity. TPS was assessed as a continuous 187 parameter in 1% increments up to 10% and 5% increments in cases showing >10% 188 expression. For statistical analyses, cases were assigned to the three clinically 189 relevant bins of TPS <1%, 1 – 49% or ≥50%. PD-L1 positive cases were defined by 190 TPS \geq 1% and strong expressing cases were defined as TPS \geq 50%.

191 Assessment of CD8 positive tumor infiltrating lymphocytes and tertiary

192 *lymphoid structures*

193 For the assessment of CD8+ TILs, only biopsies of non-lymph nodes or lymph nodes with desmoplastic reaction were eligible. We evaluated CD8+ TILs per mm² applying 194 195 a semi-automated approach using the open-source software QuPath (Supplementary figure 3) (29). First, we manually annotated regions of interest following 196 197 recommendations of the International Immuno-Oncology Biomarkers Working Group 198 (30, 31). Thus, only TILs within the borders of the invasive front of tumors were 199 evaluated and smaller satellite nodules without desmoplastic reaction were not 200 included in the assessment. In neoadjuvant cases with extensive fibrotic areas, only 201 the stroma adjacent to the tumor nests was included for analyses. Next, cells in the 202 annotated regions were segmented using the threshold-based watershed detection 203 of QuPath followed by the application of a series of object classifiers for exclusion of

anthracotic pigments and artefacts before classification and counting of CD8

205 negative and positive cells (technical manuscript in preparation). The performance of

this automated detection and classification was compared in 22 cases using 5000 x

5000 px wide squares against manual counting of one observer (PZ, Supplementarytable 1).

209 Regarding the evaluation of TLS, the digitized H&E sections were used for manual 210 assessment of the number and activity (presence of germinal centers) of TLS in the 211 resection specimens by PZ (32). In 44 cases, another block than used for PD-L1 or 212 CD8 assessment was evaluated due to the presence of larger areas of adjacent 213 normal lung tissue. All nodular aggregates of lymphocytes in the tumor region and 214 within 7 mm of the tumor border were counted (32). In cases of densely infiltrated 215 tumoral stroma, only nodular aggregates apparent on low magnification were 216 included.

217 *Statistics*

218 All analyses were conducted using R software (version 4.0.5, https://cran.r-

219 project.org/) with suitable packages. For comparison of naturally ordered categorical

220 variables or continuous variables, we used the Wilcoxon rank-sum or Kruskal-Wallis

test and for comparison of other categorical variables the Fisher's exact test.

222 Correlation was assessed using the Spearman test. Survival analyses were

223 conducted using the Log-rank test and univariable cox proportional hazard models.

224 Kaplan-Meier plots were used for the representation of survival curves. Multivariable

225 cox proportional hazard models were used for correction for confounders, which were

selected based on a significance level of $p \le 0.1$. CD8 density was included as binary

variable (low vs. high) in all survival models. It was dichotomized using maximally

- selected rank statistics based on Log-rank scores as test statistic and the
- approximation by Hothorn and Lausen for small sample sizes (33).

230 **Results**

No upregulation of PD-L1 expression by neoadjuvant therapy

232 After neoadjuvant therapy, PD-L1 expression was <1% in 43/96 (44.8%) cases, 1 -

233 49% in 31/96 (32.3%) cases and ≥50% in 22/96 (22.9%) cases. In the primary

resected cohort, PD-L1 expression was <1% in 40/114 (35.1%) cases, 1 - 49% in

235 47/114 (41.2) cases and ≥50% in 27/114 (23.7%) cases. There was no significant

236 difference in PD-L1 expression between the neoadjuvant cohort and the primary

237 resected control cohort also after adjusting for histology.

238 Except for smoking status (active smoker vs. former-/ never smoker) none of the

239 clinico-pathological parameters was associated with higher PD-L1 expression. In the

240 neoadjuvant cohort, active smoking was associated with a higher PD-L1 TPS (p =

241 0.013). Active smokers in both cohorts had a significantly higher frequency of PD-L1

positive tumors ($p_{neoadjuvant} = 0.02$, $p_{control} = 0.026$, Supplementary table 2).

243 PD-L1 expression was not significantly altered comparing paired pre-/post-

244 neoadjuvant samples. Overall, 7/57 (12.3%) tumors had lower PD-L1 expression and

245 12/57 (21.1%) had higher PD-L1 expression in the resection specimen, as assessed

regarding the clinically significant cut-offs of 1% and 50% (Figure 1, Supplementary

table 3). Four/7 cases showed lowed PD-L1 expression regarding the 50% cut-off

and 5/7 regarding the 1% cut-off (2 cases changed from ≥50% to <1%). A positive or

249 negative change of PD-L1 could not be associated with response to neoadjuvant

therapy (major pathological response [MPR] yes/no), patients' sex, tumor histology or

change of CD8 TILs density (Supplementary table 4).

252 Higher CD8 TILs density is associated with higher PD-L1 expression

253 After neoadjuvant therapy, mean CD8 TILs density within the tumor region was 254 242.45 (IQR 73.11 – 290.32) cells/mm². In the cohort of primary resected cases, mean CD8 TILs density was 252.1 (IQR 98.37 - 314.73) cells/mm². CD8 TILs 255 256 density was similar between the neoadjuvant and primary resected cohort. After 257 neoadjuvant therapy, a median of 10 (IQR 4 – 21.5) TLS were counted on the 258 selected whole slides. In the primary resected cohort, a median of 9 (IQR 4.5 - 19) 259 TLS were counted. After subgrouping according to histology, the median number of 260 TLS was comparable between histological tumor types and groups. However, there 261 were only 4 cases with active TLS in the neoadjuvant cohort compared to 13 cases in 262 the primary resected control cohort. A higher number of active TLS comparing the 263 cohorts was observed regardless of histological tumor type. 264 A higher CD8 TILs count was statistically significantly associated with LUAD 265 histology ($p_{neoadjuvant} = 0.001$, $p_{control} = 0.017$) and a higher PD-L1 expression 266 $(p_{neoadiuvant} = 0.027 R_s = 0.23, p_{control} = 0.003 R_s = 0.28, Figure 2A)$. However, when 267 subgrouping according to histological tumor type, PD-L1 expression did no longer 268 significantly correlate with CD8 TILs density in LUAD after neoadjuvant treatment. 269 Similar results were observed when applying the clinical cut-offs at 1% or 50% PD-L1 270 expression (Figure 2B-C). Among the primary resected cases, PD-L1 positive cases 271 showed a higher CD8 TILs density. After neoadjuvant therapy, this remained true 272 only for non-LUAD tumors. Strong PD-L1 expression correlated with CD8 TILs 273 density in LUAD or non-LUAD tumors in both cohorts. In primary resected cases, tumor size inversely correlated with CD8 TILs density ($R_s = -0.24$, p = 0.011), 274

275 whereas in cases after neoadjuvant treatment, higher numbers of TLS correlated with

276 higher CD8 TILs density ($R_s = 0.27$, p = 0.009).

277 CD8 TILs density was significantly lower before neoadjuvant therapy comparing 278 paired samples (p = 0.031, Figure 1, Supplementary figure 4). We performed 279 subgroup analyses to check whether changes of CD8 TILs density were associated 280 with changes in PD-L1 expression. However, changes of CD8 TILs density were only 281 significant in the subgroups of cases with no change of PD-L1 expression regarding 282 the three-fold classification of cut-offs (Supplementary figure 5), presumably due to 283 insufficient sample size in the other subgroups. Furthermore, higher CD8 density 284 before or after neoadjuvant therapy was not associated with an increase of PD-L1 285 expression.

286 Prognostic significance of immune related biomarkers

287 In the entire study population, PD-L1 expression assessed in resection specimens

had no prognostic significance, neither for OS nor for DFS, neither using 1% nor 50%

as cut-offs (Supplementary figure 6). In subgroup analyses including only cases after

290 neoadjuvant therapy or primary resected cases, PD-L1 positivity was a prognostic

291 marker for longer OS in the cohort of primary resected NSCLC (p = 0.029, HR

292 0.5255, 95% CI 0.2924 – 0.9444, Figure 3). Regarding PD-L1 as a dynamic marker,

293 patients with increased PD-L1 expression seemed to have worse 5-year OS,

however, not statistically significant (Figure 4).

295 We used maximally selected rank statistic to determine the adequate cutoff for CD8

TILs density at 283.18 cells/mm² in the entire study population. Overall, higher CD8

TILs numbers were associated with longer OS (p = 0.014, HR 0.5373, 95% CI 0.3251

298 - 0.888, Figure 5A) and longer DFS (p = 0.008, HR 0.5707, 95% Cl 0.3762 - 0.8656,

Figure 5D). In the subgroup analyses, however, it was a positive prognostic factor for

300 OS only in the cohort of neoadjuvant cases (p = 0.029, HR 0.4332, 95% CI 0.1997 –

301 0.9397, Figure 5B) and for DFS only in the cohort of primary resected cases (p =

302 0.048, HR 0.5513, 95% CI 0.3043 – 0.9986, Figure 5F).

- 303 The number of TLS was considered as a continuous variable and it was a prognostic
- marker considering the entire study population (p = 0.045, HR 0.9833, 95% CI
- 0.9673 0.9996) but not in the sub cohorts ($p_{neoadjuvant} = 0.15$, $p_{control} = 0.15$).
- 306 We investigated the validity of the prognostic significance only in the overall
- 307 population to achieve sufficient sample size and number of events. As the three
- 308 immune markers PD-L1 expression, CD8 TILs and TLS correlated significantly, we
- 309 performed a cox regression analysis for each marker. PD-L1 expression was
- 310 included using the TPS 1% cut-off only. None of the immune markers was prognostic
- in the multivariable model for OS ($p_{PD-L1} = 0.241$, $p_{CD8} = 0.368$, $p_{TLS} = 0.246$) or DFS
- 312 $(p_{PD-L1} = 0.054, p_{CD8} = 0.098, p_{TLS} = 0.407)$ but age and pT4 were consistent
- 313 prognostic factors in the multivariable models (Supplementary figure 7).

314 **Discussion**

315 In this study on immune related biomarkers in locally advanced resectable NSCLC. 316 CD8 TILs and TLS were prognostic factors but did not yield additional information to 317 age and TNM in multivariable analyses. CD8 TILs density correlated with PD-L1 318 expression. PD-L1 expression was not consistently upregulated after neoadjuvant 319 chemotherapy, in line with some, but not all previous studies. (13, 16, 19-22) 320 The effect of chemotherapy on PD-L1 expression in the resectable setting has been 321 previously investigated as summarized in Table 1 (11-22). Most studies reported an 322 increased PD-L1 expression after chemotherapy when assessing paired samples. 323 The importance of the PI3K/ALK pathway in PD-L1 upregulation after chemotherapy 324 was demonstrated in *in vitro* and *in vivo* functional assays (14, 19). Conversely, some 325 studies showed no change or even a decreased PD-L1 expression following

326 chemotherapy (11, 12, 15, 17, 18). In fact, when reassessing the positive studies and 327 considering the absolute number of cases per category (*decrease*, *no change*, 328 increase), most cases did not change. Of the four studies conducted using an FDA 329 approved antibody, only one concluded an increased PD-L1 expression post-330 chemotherapy (15, 17, 18, 20). Thus, our study results are in line with previous 331 reports for FDA approved antibodies and suggest that dynamic changes in PD-L1 332 expression due to chemotherapy are observed only in a minority of tumors. In the 333 majority of our cases (38/57) PD-L1 expression was stable and most of them were 334 negative (23/38 cases) in both the biopsy/cytology specimens and the resection after 335 neoadjuvant therapy. Considering these and previously reported results, it seems 336 unlikely that neoadjuvant chemotherapy induces PD-L1 expression. 337 Chemotherapy is deemed to improve immunosurveillance by different effects 338 (antigenicity, immunogenicity, susceptibility) (34). This would suggest an upregulation 339 of PD-L1 in tumor cells to evade a strong antitumor response. A potential explanation 340 for the lack of consistent upregulation in clinical samples could be the influence of 341 chemotherapy on the immune microenvironment. Two larger studies have 342 investigated such effects in detail by applying multiplex immunofluorescence and a 343 multiomics approach (16, 35). Both studies describe an increase of immune cells in 344 specimens after neoadjuvant therapy and point out that different subgroups of 345 immune cells are increased depending on the underlying histological tumor type (16, 346 35). However, the multiomics approach indicated no increase of T-cell receptor 347 richness and clonality, thus failed to suggest increased antigenicity or susceptibility 348 (35). Importantly, these studies did not include paired samples and, especially the 349 study using multiomics, included only few samples in their analyses (n = 10 - 72) 350 depending on experiment) (35).

351 In order to account for the immune microenvironment, we assessed the CD8 TILs 352 density and number and state of TLS. By applying a semiautomatic approach, we 353 were able to count CD8 TILs in the entire tumor region of the slides used for PD-L1 354 assessment, in contrast to the published studies usually performing hot spot analysis. 355 Although we confirmed published results indicating an increase of TILs in tumors 356 resected after neoadjuvant therapy, we cannot conclude that chemotherapy 357 increases CD8 TILs densities due to (a) no significant difference in CD8 density 358 between cases resected after neoadjuvant therapy and primary resected cases. (b) 359 biopsies covering much smaller tissue areas than whole slides (thus being more 360 prone to sampling error due to heterogeneity), and (c) higher variance in post-361 neoadjuvant therapy specimens leading to higher median ranks and means due to 362 outliers (implications for statistical testing). 363 Another explanation, comparing preclinical and clinical studies, could be the 364 heterogeneity of applied chemotherapeutic regimens, inherent in our real-life cohort 365 approach. Although, most cytotoxic agents have immunosurveillance enhancing 366 effects, these differ considerably (34). Thus, while oxaliplatin and gemcitabine have 367 been shown to promote immunogenic cell death especially via exposure of 368 calreticulin, others do not without addition of radiotherapy (e.g. cisplatin) (34, 36). 369 Furthermore, although Zhang et al. and Fournel et al. suggest an upregulation of PD-370 L1 via the PI3K/ALK pathway, earlier studies support rather the downregulation of 371 suppressive checkpoints via the STAT pathway (14, 19, 36). In our study, the 372 majority of patients (n = 54) received cisplatin and docetaxel, but only 12/54 received 373 additional radiotherapy (36). On the other hand, the few patients who had received 374 gemcitabine and had available paired samples (n = 2) showed PD-L1-upregulation 375 despite the lack of neoadjuvant radiotherapy, and only 3/11 cases were PD-L1 376 negative in the resection specimens.

377 The prognostic power of PD-L1 expression as a double-edged sword has already 378 been described exhaustively in advanced NSCLC and a high PD-L1 expression does 379 not seem to be consistently associated with worse survival (37). Likewise, most 380 studies including tumors after neoadjuvant therapy reported no prognostic 381 importance of PD-L1 expression (11, 15, 18, 20-22). In this study, static PD-L1 382 expression, evaluated only in the resection specimens, was not prognostic. However, 383 when looking at the dynamic changes, increased PD-L1 expression seemed to 384 confer worse survival, in accordance with previous studies (12, 14, 15, 21). This 385 effect can be explained by PD-L1 expression potentially conveying chemoresistance 386 and promoting proliferation and epithelial to mesenchymal transition (14, 38). High 387 CD8 TILs were always associated with improved OS. This seems to be true even 388 when applying different cut-offs, as most of the published studies used the median, 389 thus a cohort specific cut-off (11, 15, 18, 22, 39). Furthermore, the prognostic impact 390 of a higher CD8 TILs density is a possible explanation for the prognostic benefit of 391 PD-L1 positivity in primary LUSC, due to the positive correlation of PD-L1 expression 392 and CD8 TILs. In our cohort, however, CD8 TILs lost its prognostic relevance in 393 multivariable analyses including age and the pT denominator of the TNM 394 classification. Thus, we cannot confirm the importance of the immune pattern as a 395 complementary factor for survival prediction, as proposed by Remark and colleagues 396 (11).

This retrospective study assessed the impact of chemotherapy on biomarkers for ICB in a real-life cohort resected after neoadjuvant therapy over a period of 16 years. The availability of paired samples for 57 patients is comparable to prior studies but the addition of a matching cohort of primary resected locally advanced NSCLC allowed the validation of identified effects. In contrast to most published studies, we evaluated PD-L1 expression according to the current diagnostic recommendations and using an 18 FDA-approved antibody assay for companion diagnostics (40-42). Furthermore, we
included the impact on the immune microenvironment by evaluating CD8 TILs and
TLS. By applying new techniques enabled by digital pathology approaches, we could
reliably assess CD8 TILs in the same area as the PD-L1 expression and were not
restricted to hotspot analyses.

408 Nevertheless, our study has limitations inherent to its retrospective and "real-life" 409 character. Especially compared to clinical studies investigating the effect of radio-410 chemotherapy, patients with different chemotherapeutic regimens were included (15, 411 18). Although patients with changed PD-L1 expression after neoadjuvant therapy did 412 not differ regarding duration of neoadjuvant therapy or therapy free interval between 413 the last cycle of neoadjuvant therapy and resection, especially these differences in 414 duration of therapy and therapy free interval need to be accounted for when 415 interpreting our results. 416 In conclusion, our results support the hypothesis of dynamic effects of neoadjuvant 417 chemotherapy on PD-L1 expression and CD8 TILs. Overall, the majority of our cases 418 were PD-L1 negative and showed no increase in PD-L1 expression after neodjuvant 419 therapy. Nevertheless, in those cases with increased PD-L1 expression after 420 neoadjuvant therapy, 5-year OS was shorter compared to patients with no change or 421 decreased PD-L1 expression. This result could be visually appreciated, but lacked 422 statistical significance, most probably due to the very low number of cases. 423 Subsequent clinical trials are warranted in order to determine if PD-L1 retesting 424 should be performed after neoadjuvant therapy due to therapeutic implications of an 425 altered PD-L1 expression.

426 Additional Information

427 Acknowledgment

- 428 The authors are very thankful for the expert technical support of the Translational
- 429 Research Unit of the Institute of Pathology, University of Bern. We acknowledge the
- 430 Cancer registry Bern for acquiring extensive follow-up data of the patients.

431 *Authors' contribution*

- 432 Philipp Zens: Conceptualization, Data curation, Formal analyses, Funding
- 433 acquisition, Methodology, Visualization, Writing original draft, Writing Review &
- 434 Editing; Corina Bello: Data Curation, Writing Review & Editing; Amina Scherz: Data
- 435 Curation, Writing Review & Editing; Michael von Gunten: Resources, Writing –
- 436 Review & Editing; Adrian Ochsenbein: Resources, Writing Review & Editing; Ralph
- 437 A. Schmid: Resources, Writing Review & Editing; Christina Neppl: Resources,
- 438 Writing Review & Editing; Sabina Berezowska: Conceptualization, Data curation,
- 439 Formal analyses, Funding acquisition, Methodology, Project administration,
- 440 Resources, Supervision, Writing original draft, Writing Review & Editing
- 441 Ethics approval and consent to participate
- 442 This study was approved by the Cantonal Ethics Committee of the canton of Bern
- 443 waiving the requirement of informed consent (KEK 2017-00830). The study was
- 444 performed in accordance with the Declaration of Helsinki.
- 445 Data availability
- 446 Anonymized detailed clinico-pathological data and the R-Script used for data analysis
- 447 are available upon request to the authors.

448 Competing Interests

449 SB has served as compensated consultant for Basilea, Eli Lilly, MSD and Roche

450 (payment to institution) and has received research funding from Roche outside of the

- 451 current project. The other authors declare no conflict of interest.
- 452 Funding information
- 453 The study was supported by grants from the Stiftung zur Krebsbekämpfung
- 454 (SKB425) and Cancer Research Switzerland (KFS-4694-02-2019) to SB. PZ is
- 455 supported by a MD-PhD scholarship of Cancer Research Switzerland (MD-PhD-
- 456 5088-06-2020). The funding agencies had no role in study design, in the collection,
- 457 analysis and interpretation of data, in the writing of the report or in the decision to
- 458 submit the article for publication. Open Access funding provided by the University of
- 459 Lausanne.

461 **References**

462 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soeriomataram I, Jemal A, et al. 463 Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality 464 worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. 465 Howington JA. Blum MG. Chang AC. Balekian AA. Murthy SC. Treatment of 2. 466 stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 467 3rd ed: American College of Chest Physicians evidence-based clinical practice 468 guidelines. Chest. 2013;143(5 Suppl):e278S-e313S. 469 3. Souquet PJ, Geriniere L. The role of chemotherapy in early stage of non-small 470 cell lung cancer. Lung Cancer. 2001:34 Suppl 2:S155-8. 471 Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et 4. 472 al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical 473 Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 474 2017;28(suppl 4):iv1-iv21. 475 Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens 5. 476 RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE 477 Collaborative Group. J Clin Oncol. 2008;26(21):3552-9. 478 Spicer J, Wang C, Tanaka F, Saylors GB, Chen K-N, Liberman M, et al. 6. 479 Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + 480 platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment 481 for patients with resectable non-small cell lung cancer (NSCLC). Journal of Clinical 482 Oncology. 2021;39(15_suppl):8503-. 483 7. Wakelee HA, Altorki NK, Zhou C, Csőszi T, Vynnychenko IO, Goloborodko O, 484 et al. IMpower010: Primary results of a phase III global study of atezolizumab versus 485 best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small 486 cell lung cancer (NSCLC). Journal of Clinical Oncology. 2021;39(15_suppl):8500-. 487 8. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune 488 Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069-86. 489 9. Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or 490 in combination with chemotherapy, as first-line treatment for advanced non-small cell 491 lung cancer. A systematic review and network meta-analysis. Lung Cancer. 492 2019;134:127-40. 493 Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive 10. 494 biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 495 2019;16(6):341-55. 496 Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, et al. Immune 11. 497 contexture and histological response after neoadjuvant chemotherapy predict clinical 498 outcome of lung cancer patients. Oncoimmunology. 2016;5(12):e1255394. 499 Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, et al. Expression of 12. 500 programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-501 small cell lung cancer. Sci Rep. 2016;6:20090. 502 13. Song Z, Yu X, Zhang Y. Altered expression of programmed death-ligand 1 503 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. 504 Lung Cancer. 2016;99:166-71. 505 14. Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, et al. Upregulation of 506 programmed cell death ligand 1 promotes resistance response in non-small-cell lung 507 cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 508 2016;107(11):1563-71.

509 Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, et al. Alteration 15. 510 of PD-L1 expression and its prognostic impact after concurrent chemoradiation 511 therapy in non-small cell lung cancer patients. Sci Rep. 2017;7(1):11373. 512 Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, et al. 16. 513 Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small 514 cell lung carcinomas as determined by multiplex immunofluorescence and image 515 analysis approaches. J Immunother Cancer. 2018;6(1):48. 516 17. Rojko L, Reiniger L, Teglasi V, Fabian K, Pipek O, Vagvolgyi A, et al. 517 Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer 518 patients. J Cancer Res Clin Oncol. 2018;144(7):1219-26. 519 Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, et al. Dynamic 18. changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung 520 521 cancer following chemoradiation therapy. Lung Cancer. 2019;136:30-6. 522 Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G, et al. Cisplatin 19. 523 increases PD-L1 expression and optimizes immune check-point blockade in non-524 small cell lung cancer. Cancer Lett. 2019;464:5-14. 525 Guo L, Song P, Xue X, Guo C, Han L, Fang Q, et al. Variation of Programmed 20. 526 Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in 527 Lung Cancer. J Immunother. 2019;42(6):215-20. 528 Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, et al. Effect of Platinum-21. 529 Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung 530 Cancer. Cancer Res Treat. 2019;51(3):1086-97. 531 22. Yoneda K, Kuwata T, Kanayama M, Mori M, Kawanami T, Yatera K, et al. 532 Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating 533 lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J 534 Cancer. 2019;121(6):490-6. 535 Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et 23. 536 al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 537 Immunity. 2016;44(2):343-54. 538 24. Zens P, Bello C, Scherz A, Koenigsdorf J, Pollinger A, Schmid RA, et al. A 539 prognostic score for non-small cell lung cancer resected after neoadiuvant therapy in 540 comparison with the tumor-node-metastases classification and major pathological 541 response. Mod Pathol. 2021. Brierley JD GM, Wittekind C. International Union Against Cancer (UICC): TNM 542 25. 543 Classification of Malignant Tumours. 8 ed. Oxford: Wiley-Blackwell; 2017. 544 26. WHO Classification of Tumours. Thoracic Tumours. 5 ed. Lyon: International 545 Agency for Research on Cancer; 2021. 546 27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. 547 Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl 548 Cancer Inst. 2005;97(16):1180-4. 549 Dirnhofer S, Bubendorf L, Lehr H-A, Landau B, Zenklusen H-R. 28. 550 Qualitätsrichtlinien SGPath. 2011(1.). 551 29. Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne 552 PD, et al. QuPath: Open source software for digital pathology image analysis. Sci 553 Rep. 2017;7(1):16878. 554 30. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. 555 Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International 556 557 Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune 558 Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ,

559 Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 560 2017;24(5):235-51. 561 Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. 31. 562 Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for 563 Pathologists and Proposal for a Standardized Method from the International Immuno-564 Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal 565 Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial 566 and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, 567 Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 568 2017;24(6):311-35. 569 Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. 32. 570 Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid 571 Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. 572 Cancer Res. 2018;78(5):1308-20. 573 33. Hothorn T, Lausen B. On the exact distribution of maximally selected rank 574 statistics. Computational Statistics & Data Analysis. 2003;43(2):121-37. 575 Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of 34. 576 conventional and targeted anticancer therapies: reinstating immunosurveillance. 577 Immunity. 2013;39(1):74-88. 578 Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, et al. 35. 579 Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T 580 Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021;16(1):127-581 39. 582 36. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the 583 immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 584 2014;20(11):2831-7. 585 Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y. The Significance of 37. 586 the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as 587 Predictive and Prognostic Markers. Clin Lung Cancer. 2018;19(2):120-9. 588 Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, et al. 38. 589 Clinical and pathologic features of lung cancer expressing programmed cell death 590 ligand 1 (PD-L1). Lung Cancer. 2016;98:69-75. 591 Chen L, Cao MF, Zhang X, Dang WQ, Xiao JF, Liu Q, et al. The landscape of 39. 592 immune microenvironment in lung adenocarcinoma and squamous cell carcinoma 593 based on PD-L1 expression and tumor-infiltrating lymphocytes. Cancer Med. 594 2019;8(17):7207-18. 595 Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hirsch FR. IASLC Atals of PD-L1 40. 596 immunohistochemistry testing in lung cancer. 2017. 597 Naito T, Udagawa H, Sato J, Horinouchi H, Murakami S, Goto Y, et al. A 41. 598 Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess 599 Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to 600 Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. J Thorac 601 Oncol. 2019;14(10):1818-27. 602 Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved 42. 603 Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021;23(2):39. 604

606 Figure legends

607 **Figure 1:** Immunohistochemical slides of two cases in the study cohort with altered

- 608 PD-L1 expression and TILs density after neoadjuvant therapy. Pre-neoadjuvant and
- 609 post-neoadjuvant sections stained for CD8 and PD-L1 are represented. Patient 002
- 610 changed from 40% TPS to 100% TPS and CD8+ TILs density doubled in the
- 611 resection specimen. Patient 060 changed from 100% TPS to <1% TPS and CD8+
- 612 TILs density halved in the resection specimen. Objective magnification 20x, scalebar
- 613 50 µm.
- 614 Figure 2: CD8+ TILs density according to PD-L1 expression using the (A) threefold
- 615 classification, (B) 1% TPS cutoff and (C) 50% TPS cutoff.
- 616 **Figure 3:** Kaplan-Meier plots of PD-L1 expression as a prognostic biomarker in the
- 617 (A, C) study cohort and (B, D) control cohort according to the (A, B) 1% TPS cutoff
- 618 and (C, D) 50% TPS cutoff.
- 619 **Figure 4:** Prognostic importance of the dynamic of PD-L1 change based on the
- 620 three-fold classification when considering all (A) possibilities or differentiating only
- 621 between increase and others (B).
- 622 **Figure 5:** Kaplan-Meier plots of CD8 TILs density as a prognostic biomarker
- 623 regarding (A-C) OS and (D-F) DFS in the (A, D) entire study population, (B, E) the
- 624 study cohort and (C, F) the control cohort.

study	year	number of patients	histology	paired samples (pre- /post-	neoadjuvant treatment	PD-L1 clone	PD-L1 evaluation	PD-L1 change	negative/ no change	CD8 clone	CD8 evaluation	CD8 change
				neo- adjuvant)								
Remark [11]	2016	21	LUSC/ LUAD/LCC	yes	chemotherapy	E1L3N	Semi- quantitative	no change	-	SP16	manually	no change
Sheng [12]	2016	32	LUSC/LUAD	yes	chemotherapy	E1L3N	Semi- quantitative	decrease	-	-	-	-
Song [13]	2016	76	LUSC	yes	chemotherapy	PD-L1	Semi- quantitative	increase	31/65	-	-	-
Zhang [14]	2016	30	LUSC/LUAD	yes	chemotherapy	Abcam	Semi- quantitative	-	-	-	-	-
Fujimoto [15]	2017	35	LUSC/LUAD	yes	chemoradiotherapy	28-8	TPS	decrease	11/15	C8/144B	Semi- quantitative	increase
Parra [16]	2018	112	LUSC/LUAD	no	chemotherapy	E1L3N*	automated	increase	-	C8/144B (fluorescent)	automated	no change
Rojko [17]	2018	41	LUSC/LUAD/ NSCLC/SCLC	yes	chemotherapy	SP142	Semi- quantitative	no change	-/29	H&E	Semi- quantitative	no change
Choe [18]	2019	33	LUSC/LUAD	yes	chemoradiotherapy	22C3 SP263	TPS	no change	13/16	C8/144B	Semi- quantitative	increase
Fournel [19]	2019	39	LUSC/LUAD/ LCNEC	yes	chemotherapy	E1L3N	TPS	increase	-/8	SP16	automated	no change
Guo [20]	2019	63	LUSC/LUAD/ LCNEC	yes	chemotherapy	22C3	TPS	increase	-/40	-	-	-
Shin [21]	2019	86	LUSC/LUAD	yes	chemotherapy	E1L3N	TPS	increase	15/40	-	-	-

Table 1: Currently published studies investigating the effect of neoadjuvant regimens on PD-L1 expression and the immune microenvironment.

Yoneda	2019	41	LUSC/LUAD	yes	Chemotherapy,	E1L3N	TPS	increase	-	C8/144B	manually	increase
[22]					chemoradiotherapy			(CCRT),				
								no				
								change				
								(CT)				
								no				
								change				
								(CT)				

LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; LCC, large cell carcinoma; NSCLC, non-small cell lung canrcinoma; CCRT, concurrent chemoradiotherapy; CT, chemotherapy; *, fluorescent

	Study Cohort	Control Cohort	
	(n = 96)	(n = 114)	p value
age (median [IQR])	63.50 [55.75, 70.00]	63.50 [58.00, 70.00]	0.418°
sex (%)	n = 96 (%)	n = 114 (%)	0.553*
female	28 (29.2)	38 (33.3)	
male	68 (70.8)	76 (66.7)	
smoking status (%)	n = 83 (%)	n = 90 (%)	0429*
never/ex-smoker	56 (67.5)	55 (61.1)	
active smoker	27 (32.5)	35 (38.9)	
histology (%)	n = 96 (%)	n = 114 (%)	0.678*
LUSC	46 (47.9)	54 (47.4)	
LUAD	47 (49.0)	60 (52.6)	
other	3 (3.1)		
tumor size (median [IQR])	3.20 [2.00, 4.85]	4.75 [3.00, 6.07]	<0.001°
Major pathological response (%)	n = 96 (%)		
MPR	33 (34.4)		
No MPR	63 (65.6)		
(y)pT (%)	n = 96 (%)	n = 114 (%)	0.027°
(y)pTO	1 (1.0)		
(y)pT1	32 (33.3)	17 (14.9)	
(y)pT2	22 (22.9)	37 (32.5)	
(y)pT3	20 (20.8)	31 (27.2)	
(y)pT4	21 (21.9)	29 (25.4)	
stage (%)	n = 96 (%)	n = 114 (%)	
	17 (17.7)		
	25 (26.0)		
	50 (52.1)	104 (91.2)	
	4 (4.2)	10 (8.8)	
growth pattern (%)		n = 58 (%)	
acinar/papillary		15 (25.9)	
solid		20 (40.3)	
turns of respection (%)	n – 06 (%)	15(25.9)	0.496*
type of resection (%)	n = 96 (%)	n = 114 (%)	0.480
labastomy	52 (55 2)	5 (2.0) 62 (54 4)	
hilobectomy	5 (5 2)	8 (7 0)	
nneumonectomy	38 (39 6)	41 (36 0)	
neoadiuvant therapy (%)	n = 94.0%		
Cisnlatin + Docetavel	54 (57 A)		
Carbonlatin + Paclitaxel	5 (5 2)		
Cisplatin + Pemetrexed	13 (13.8)		
Cisplatin + Gemcitabine	8 (8.5)		
	- ()	I	I

Table 2: Baseline characteristics of the study and control cohort.

Cisplatin + Vinorelbine	5 (5.3)		
Cisplatin + Etoposide	1 (1.1)		
Other	8 (8.5)		
adjuvant therapy (%)	n = 88 (%)	n = 99 (%)	<0.001*
no	65 (73.9)	32 (32.3)	

No statistical comparison of stage, growth patterns, residual tumor and neoadjuvant therapy due to inherent differences.

* Fisher's exact test, ° Wilcoxon rank-sum test. Main variable names and p-values are bold. Statistically significant p-values are red.

resection



PID 060

PID 002

biopsy





1.00 0.75 -Cumulative Survival PD-L1 expression + <50% **+** ≥50% Log-rank 0.25 p = 0.57 0.00 -12 48 24 60 ò 36 Overall Survival [months] 5-year Overall Survival according to 50% PD-L1 expression D 1.00 -0.75 -Cumulative Survival PD-L1 expression <50% + **+** ≥50% Log-rank 0.25 p = 0.57 0.00 -

48

60

12

24

Overall Survival [months]

36

ò





unchanged





5-year Overall Survival according CD8 density in the study cohort В



С 5-year Overall Survival according CD8 density in the control cohort





5-year Disease-free Survival according CD8 density in the study cohort Е







5-year Disease-free Survival according CD8 density